Multiple myeloma (2L+; post-anti CD38)
Indication: NSCLC
Title: Open-Label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzamab, Pomalidomide, and Dexamethasone (ELOPd) in Patients with Relapses or Refractory Multiple Myeloma (RRMM)
Drug: Selinexor
Please visit clinicaltrials.gov for more information about this study
This trial is for selinexor.
Phase 1 | Phase 2 | Phase 3 | Commercial |
---|---|---|---|
Phase 1 | Phase 2 | Phase 3 | Commercial |